92% of potential cancer drugs fail in clinical trials, so Pharma has a huge need for new clinical candidates for its pipeline. PercepTx meets this need via efficient model-guided pre-clinical development of antibody-drug conjugates (ADCs), an established targeted cancer therapy modality. We are developing a pipeline of ADCs for out-licensing to big pharma/biotech, fueled by investment, service revenue and research collaborations to an M&A exit.